Popular Trials
Opioid Antagonist
Low-Dose Naltrexone for Diabetic Neuropathy
This trial is testing Low-Dose Naltrexone (LDN) to see if it can help people with diabetes who have painful neuropathy in their legs and feet. LDN aims to reduce pain by enhancing the body's natural pain relief and decreasing inflammation. The study hopes to find a safer, non-opioid alternative for managing this difficult-to-treat pain.
Procedure
cTMS for Diabetic Neuropathy
This trial will assess the effects of cTMS, a non-invasive form of brain stimulation, on diabetic neuropathic pain. Previous research has shown that it can reduce pain, but only works for ~50% of patients. This trial has the potential to make transformative changes in pDN & improve pain relief.
Popular Filters
Trials With No Placebo
Behavioural Intervention
Non-Pharmacological Therapy for Diabetic Neuropathy
This trial will test if a non-medicine device can reduce pain, improve quality of life and prevent deaths from diabetes nerve damage. 16 participants with/without diabetes will try it over 10 days. Results will show if it works.
Omega-3 Fatty Acid
Fish Oil + Salsalate for Diabetic Neuropathy
This trial is studying the combination of fish oil and salsalate to see if it is an effective treatment for diabetic peripheral neuropathy (DPN). DPN is a common complication of diabetes that can lead to severe pain, sensory deficits, foot ulcers, and amputations. There is no currently no effective treatment for DPN.
Behavioural Intervention
Lifestyle Modification for Diabetic Neuropathy
This trial will test an aerobic exercise and balance intervention in participants with impaired glucose regulation (IGR). The investigators will examine if this intervention can improve autonomic function and balance control when compared to patients who receive standard care.
View More Related Trials
Frequently Asked Questions
Introduction to diabetic neuropathy
What are the top hospitals conducting diabetic neuropathy research?
In the realm of clinical trials for diabetic neuropathy, several hospitals are making strides in exploring innovative treatments and improving patients' quality of life. Truwell Health, located in Saint Petersburg, is one such institution that has dedicated its efforts to this condition. While currently conducting one active trial for diabetic neuropathy and having completed just a single trial thus far, their commitment to research and advancement is evident. In another part of Florida, the renowned medical facility Florida Pain management Associates, P.A., with locations both in Sebastian and Vero Beach, joins the ranks with equal enthusiasm. They too have initiated one ongoing clinical trial focused on diabetic neuropathy and have undertaken a sole previous study as well.
Further expanding this landscape is Centurion Spine and Pain Centers situated in Brunswick alongside Waycross—both contributing significantly to the understanding of diabetic neuropathy through their active engagement in current trials while also recording only a solitary completed study each since 2022 being their pioneering year.
Though these numbers may appear modest compared to larger institutions or more established fields within medical research, they highlight essential contributions made by these hospitals towards addressing an underrepresented aspect of diabetes-related complications. Diabetic neuropathy can cause debilitating pain and functional impairment for individuals affected by it; therefore any progress made through these clinical trials holds significant potential for alleviating suffering experienced by countless patients worldwide.
Which are the best cities for diabetic neuropathy clinical trials?
When it comes to clinical trials for diabetic neuropathy, several cities are emerging as frontrunners in research. Winston-Salem, North carolina; Hinsdale, Illinois; Miramar, Florida; Saint Louis, Missouri; and Baltimore, Maryland each have 2 active trials focused on finding effective treatments. These studies explore a range of interventions such as Axon Therapy + CMM and 10 kHz SCS plus CMM in Winston-Salem, Active tDCS + Active TUS in Hinsdale, Erchonia® EVRL™ in Miramar, Fish-oil derived n-3 polyunsaturated fatty acids in Saint Louis, and lifestyle modification approaches in Baltimore. By conducting these trials across multiple locations nationwide, researchers are working towards improving the lives of individuals with diabetic neuropathy through innovative therapies and strategies.
Which are the top treatments for diabetic neuropathy being explored in clinical trials?
Exciting advancements are taking place in clinical trials for the treatment of diabetic neuropathy. In particular, active transcranial direct current stimulation (tdcs) combined with active transcutaneous ultrasound (TUS), Erchonia® EVRL™ therapy, fish oil concentrate oral capsules, and fish-oil derived n-3 polyunsaturated fatty acids have emerged as top contenders. Each treatment is currently being explored in one active trial dedicated to diabetic neuropathy. These innovative therapies showcase promising potential and offer hope for improving the lives of those affected by this condition.
What are the most recent clinical trials for diabetic neuropathy?
Recent clinical trials for diabetic neuropathy offer hope and potential advancements in treatment. One noteworthy trial focuses on the use of eptinezumab, a drug that shows promise in addressing the symptoms of diabetic neuropathy. Additionally, fish oil concentrate in oral capsule form has undergone Phase 1 and Phase 2 trials to assess its efficacy in managing this condition. Another innovative approach involves combining active transcranial direct current stimulation (tdcs) with active transcutaneous ultrasound stimulation (TUS). This combination therapy is being studied to determine its effectiveness in alleviating symptoms associated with diabetic neuropathy. Lastly, naltrexone and pregabalin are also subjects of investigation as possible treatments for this challenging condition. With ongoing research into these various interventions, new possibilities may emerge that can improve the lives of individuals living with diabetic neuropathy.
What diabetic neuropathy clinical trials were recently completed?
In the realm of diabetic neuropathy, several recent clinical trials have reached completion, showcasing promising advancements in treatment options. Notably, Eli Lilly and Company concluded a trial for LY3526318 in January 2022, while Regenacy Pharmaceuticals LLC completed their ricolinostat study in December 2020. Additionally, WinSanTor Inc.'s topical solution Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) saw its trial come to an end in November 2020. These trials, along with others like ETX-018810 by Eliem Therapeutics and LY3016859 by Eli Lilly and Company, provide hope for individuals affected by diabetic neuropathy and signify significant progress towards improved care strategies.